Repaglinide Tablets is a medication used for the treatment of type 2 diabetes. It contains repaglinide as the main ingredient, which helps control blood sugar levels. It is suitable for adult diabetes patients who cannot effectively control high blood sugar through diet control, weight reduction, and exercise alone. Repaglinide Tablets can be used alone or in combination with metformin.
This document is the official package insert (instruction leaflet) for NovoNorm Repaglinide Tablets, manufactured by Novo Nordisk. It provides comprehensive information regarding the drug's usage, dosage, indications, and safety profile for adult patients with Type 2 diabetes mellitus who require additional treatment alongside diet, weight reduction, and exercise. The text is written in Chinese and includes specific instructions on administration, such as taking the medication 15 minutes before meals, with available strengths of 0.5mg, 1.0mg, and 2.0mg.
The insert details the pharmacological properties, including metabolism via CYP2C8 and CYP3A4 enzymes, and highlights potential drug interactions, specifically warning against concurrent use with Gemfibrozil. It also lists common adverse reactions like hypoglycemia and provides guidelines for special patient populations, including those with liver or kidney impairment, as well as precautions for driving and operating machinery.
| Chemical Formula | C27H36N2O4 |
|---|---|
| Molecular Weight | 452.6 |
| Available Strengths | 0.5mg, 1.0mg, 2.0mg |
| Metabolism Enzymes | CYP2C8, CYP3A4 |
The tablets should be taken 15 minutes before meals, or within 0-30 minutes before a meal.
The maximum recommended daily dose should not exceed 16mg.
No, Repaglinide and Gemfibrozil should not be used together due to significant increases in plasma drug concentration.
The most common adverse reaction is hypoglycemia (low blood sugar).